Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ALinC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study

NCT00003783 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00003783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ALinC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
March 31, 1999
Completion date
March 31, 2007
Enrollment
36 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia